AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, today announced the appointment of Mr. Chao Feng as an independent director. Mr. Feng, a seasoned executive that has previously worked for two US Fortune 500 Companies in China, will be succeeding Ms. Lin Yu who resigned as a director of the company for personal reasons. Ms. Lin Yu’s resignation and Mr. Feng’s appointment both went into effect as of July 19, 2021. “I welcome Mr. Chao Feng in joining our board of directors. His strong academic background and business management experience, particularly in strategic planning, capital market transactions and sales, will benefit our Company in our pursuit of long-term growth,” AnPac Bio-Medical Science CEO and Chairman of the board of directors Dr. Chris Yu stated in the news release. “Also, on behalf of our management team and board of directors, I would like to thank Ms. Lin Yu for her contributions to the Company.”
To view the full press release, visit https://nnw.fm/U4aVX
About AnPac Bio
AnPac Bio is a biotechnology company focused on early cancer screening and detection, with 142 issued patents as of March 31, 2021. With two certified clinical laboratories in China and one CLIA registered clinical laboratory in the United States, AnPac Bio performs a suite of cancer screening and detection tests, including CDA (Cancer Differentiation Analysis), bio-chemical, immunological, and genomics tests. According to Frost & Sullivan, AnPac Bio ranked third worldwide among companies offering next-generation early cancer screening and detection technologies in terms of the number of clinical samples for cancer screening and detection, based on approximately 41,700 clinical samples as of December 31, 2019. AnPac Bio’s CDA technology platform has been shown in retrospective validation studies to be able to detect the risk of over 20 different cancer types with high sensitivity and specificity. For more information, visit the company’s website at www.Anpacbio.com.
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork
